The Lancet Rheumatology - In line with previously published data, incidences of all-cause mortality and AESIs were similar in patients given belimumab and placebo, except for serious infusion...
Articles from: The Lancet Rheumatology
The Lancet Rheumatology - COVID-19 has been occasionally linked to histologically confirmed cutaneous vasculitis and a Kawasaki-like vasculitis, with these entities generally having minimal or no lung involvement...
-
The vasculitis of #COVID19. https://t.co/DLaZnmm9eq @TheLancetRheum Unique features w/ mimics that account for multi-organ involvement, clotting, and pulmonary vascular immunothrombois. A very insightful review/perspective https://t.co/DLaZnmm9eq
The Lancet Rheumatology - The COVID-19 pandemic has precipitated a search for both effective treatments and patient factors that predict poor outcome. Although agents ranging from convalescent plasma...
-
NEW Comment— @philipcrobinson & @EricFMorand discuss the divergent effects of acute versus chronic #glucocorticoids in #COVID19 https://t.co/rBuUKfjrD7 #LancetRheumatology
Systemic lupus erythematosus: diverting progress to chase rare side effects?
posted 1 month
Mashup Score: 2
The Lancet Rheumatology - In The Lancet Rheumatology, Saira Sheikh and colleagues report results of the BASE trial,1 a phase 4 randomised control trial designed to assess mortality...
-
"Systemic lupus erythematosus: diverting progress to chase rare side effects?" Linked comment by Joan T Merrill @OMRF https://t.co/ovWUzO76c5
Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?
posted 1 week
Mashup Score: 2
The Lancet Rheumatology - Chronic non-infectious osteomyelitis is an autoinflammatory bone disorder that can affect patients’ quality of life and psychosocial development.1,2 The disease shows substantial variation in...
-
NEW Comment—"Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?" https://t.co/fq5WozhIWQ #LancetRheumatology @ChristianHedr16 https://t.co/fq5WozhIWQ
The multifaceted problem of pulmonary arterial hypertension in systemic sclerosis
posted 1 month
Mashup Score: 2
The Lancet Rheumatology - Cardiopulmonary complications are a leading cause of death in systemic sclerosis. Pulmonary hypertension in particular carries a high mortality and morbidity burden. Patients with...
-
NEW Viewpoint—@CosimoBruni and colleagues discuss the multifaceted problem of pulmonary arterial hypertension in #SystemicSclerosis https://t.co/RyLUpyOQgu #LancetRheumatology #PAH https://t.co/RyLUpyOQgu
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study
posted 2 weeks
Mashup Score: 1
The Lancet Rheumatology - The ongoing COVID-19 pandemic caused by the novel β-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses a serious challenge for the management of...
-
NEW Comment "#COVID19 and #systemicsclerosis: clinicopathological implications from Italian nationwide survey study" https://t.co/zRhgGXWjf4
The Lancet Rheumatology - We found no evidence for efficacy of sirolimus for treating inclusion body myositis based on maximal voluntary isometric knee extension strength and other muscle...
-
44 pts of Inclusion body myositis were randomized to either PBO or sirolimus 2 mg/d. At 12 mos there were no signif differences betw groups for motor strength , but sirolimus had more SAEs (45 vs 27%); yet sirolimus had better HAQ, FVC & 6-min walk times. https://t.co/YhnRTnaGFl
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
posted 1 month
Mashup Score: 1
The Lancet Rheumatology - The risks of severe COVID-19 outcomes have improved over time in patients with rheumatic and musculoskeletal disease but remain substantial. These findings might reflect...
-
NEW RESEARCH—Temporal trends in severe #COVID19 outcomes in patients with rheumatic disease: a cohort study https://t.co/B9ZXQasNDT #LancetRheumatology @AprilJorgeMD @kmdsilvaMD @zach_wallace_md @natalie_mccor https://t.co/B9ZXQasNDT
The Lancet Rheumatology - PF-06826647 showed significant improvement in disease activity within 4 weeks of dosing with an acceptable safety profile. PF-06826647 holds promise over conventional oral treatments...
-
NEW RESEARCH—Phase 1, randomised, double-blind, placebo-controlled, parallel-group study of the TYK2 inhibitor PF-06826647 in participants with plaque #psoriasis showed improved disease activity with an acceptable safety profile https://t.co/hJvRhnrHQQ #LancetRheumatology https://t.co/hJvRhnrHQQ
NEW RESEARCH: The phase 4 BASE trial of #Belimumab in active systemic #lupus erythematosus shows that the overall benefit–risk profile for belimumab remains positive https://t.co/mY9L993dxd #LancetRheumatology https://t.co/mY9L993dxd